| 1 | J. Neurochem. 2010 Mar 112: 1273-85 |
|---|---|
| PMID | 20002525 |
| Title | DNA methylation regulates adenosine A(2A) receptor cell surface expression levels. |
| Abstract | Adenosine A(2A) receptors (A(2A)Rs) appear to play important roles in inflammation and in certain diseases of the nervous system. Pharmacological modulation of A(2A)Rs is particularly useful in Parkinson's disease and has been tested inschizophrenia。However, little is known about the regulation of A(2A)R gene (ADORA2A). A bioinformatic analysis revealed the presence of three CpG islands in the 5' UTR region of humanADORA2A。Next, HeLa, SH-SY5Y and U87-MG cells were treated for 48 h with 5 muM 5-azacytidine (Aza). Increased A(2A)R levels were demonstrated in HeLa and SH-SY5Y cells when compared with non-treated cells. No modifications were seen in U87-MG cells. The increased A(2A)R mRNA and protein levels were accompanied by a loss of DNA methylation pattern in HeLa and SH-SY5Y cells, as measured with the SEQUENOM MassArray platform. The Aza treatment also reduced the affinity of a methyl-CpG-binding protein forADORA2Aby quantitative chromatin immunoprecipitation in HeLa cells. Interestingly, A(2A)R levels were reduced by S-adenosyl-l-methionine treatment in U87-MG and methyl-CpG-binding protein affinity was increased forADORA2Aby quantitative chromatin immunoprecipitation. Therefore, these results show for the first time that DNA methylation plays a role inADORA2Atranscription and, subsequently, in constitutive A(2A)R cell surface levels. |
| SCZ Keywords | schizophrenia |
| 2 | Biol. Psychiatry 2010 Oct 68: 657-66 |
| PMID | 20691427 |
| Title | Genetic associations of brain structural networks in schizophrenia: a preliminary study. |
| Abstract | schizophreniais a complex genetic disorder, with multiple putative risk genes and many reports of reduced cortical gray matter. Identifying the genetic loci contributing to these structural alterations inschizophrenia(and likely also to normal structural gray matter patterns) could aid understanding ofschizophrenia's pathophysiology. We used structural parameters as potential intermediate illness markers to investigate genomic factors derived from single nucleotide polymorphism (SNP) arrays. We used research quality structural magnetic resonance imaging (sMRI) scans from European American subjects including 33 healthy control subjects and 18schizophreniapatients. All subjects were genotyped for 367 SNPs. Linked sMRI and genetic (SNP) components were extracted to reveal relationships between brain structure and SNPs, using parallel independent component analysis, a novel multivariate approach that operates effectively in small sample sizes. We identified an sMRI component that significantly correlated with a genetic component (r = -.536, p < .00005); components also distinguished groups. In the sMRI component,schizophreniagray matter deficits were in brain regions consistently implicated in previous reports, including frontal and temporal lobes and thalamus (p < .01). These deficits were related to SNPs from 16 genes, several previously associated withschizophreniarisk and/or involved in normal central nervous system development, including AKT, PI3K, SLC6A4, DRD2, CHRM2, andADORA2A。 Despite the small sample size, this novel analysis method identified an sMRI component including brain areas previously reported to be abnormal inschizophreniaand an associated genetic component containing several putativeschizophreniarisk genes. Thus, we identified multiple genes potentially underlying specific structural brain abnormalities inschizophrenia。 |
| SCZ Keywords | schizophrenia |
| 3 | Transl Psychiatry 2011 -1 1: e9 |
| PMID | 22832404 |
| Title | Convergent functional genomics of anxiety disorders: translational identification of genes, biomarkers, pathways and mechanisms. |
| Abstract | Anxiety disorders are prevalent and disabling yet understudied from a genetic standpoint, compared with other major psychiatric disorders such as bipolar disorder andschizophrenia。The fact that they are more common, diverse and perceived as embedded in normal life may explain this relative oversight. In addition, as for other psychiatric disorders, there are technical challenges related to the identification and validation of candidate genes and peripheral biomarkers. Human studies, particularly genetic ones, are susceptible to the issue of being underpowered, because of genetic heterogeneity, the effect of variable environmental exposure on gene expression, and difficulty of accrual of large, well phenotyped cohorts. Animal model gene expression studies, in a genetically homogeneous and experimentally tractable setting, can avoid artifacts and provide sensitivity of detection. Subsequent translational integration of the animal model datasets with human genetic and gene expression datasets can ensure cross-validatory power and specificity for illness. We have used a pharmacogenomic mouse model (involving treatments with an anxiogenic drug--yohimbine, and an anti-anxiety drug--diazepam) as a discovery engine for identification of anxiety candidate genes as well as potential blood biomarkers. Gene expression changes in key brain regions for anxiety (prefrontal cortex, amygdala and hippocampus) and blood were analyzed using a convergent functional genomics (CFG) approach, which integrates our new data with published human and animal model data, as a translational strategy of cross-matching and prioritizing findings. Our work identifies top candidate genes (such as FOS, GABBR1, NR4A2, DRD1,ADORA2A, QKI, RGS2, PTGDS, HSPA1B, DYNLL2, CCKBR and DBP), brain-blood biomarkers (such as FOS, QKI and HSPA1B), pathways (such as cAMP signaling) and mechanisms for anxiety disorders--notably signal transduction and reactivity to environment, with a prominent role for the hippocampus. Overall, this work complements our previous similar work (on bipolar mood disorders andschizophrenia) conducted over the last decade. It concludes our programmatic first pass mapping of the genomic landscape of the triad of major psychiatric disorder domains using CFG, and permitted us to uncover the significant genetic overlap between anxiety and these other major psychiatric disorders, notably the under-appreciated overlap withschizophrenia。PDE10A TAC1和其他基因发现了我们rk provide a molecular basis for the frequently observed clinical co-morbidity and interdependence between anxiety and other major psychiatric disorders, and suggest schizo-anxiety as a possible new nosological domain. |
| SCZ Keywords | schizophrenia |
| 4 | Psychiatry Res 2012 Dec 200: 126-32 |
| PMID | 22705363 |
| Title | Upregulation of adenosine A2A receptors induced by atypical antipsychotics and its correlation with sensory gating in schizophrenia patients. |
| Abstract | Sensory gating deficits have been found in patients withschizophreniaand their unaffected relatives. However, the underlying neurobiological mechanism of this deficit remains unclear. Pre-clinical studies have implicated adenosine in sensory gating deficits inschizophrenia。Therefore, the current study investigated a possible relationship between peripheral adenosine A2A receptor (ADORA2A) and sensory gating indices (P50 measures) in medication-freeschizophrenia(n=31) and healthy (n=21) groups. The effects of six-week antipsychotic treatment were examined. At baseline,schizophreniapatients showed impaired sensory gating compared to healthy controls. However, there was no significant difference inADORA2Agene expression among groups. In addition,ADORA2Aexpression was not correlated with sensory gating at any time point. Following treatment, we found a significant upregulation ofADORA2Aexpression. Intriguingly, we observed a significant positive association betweenADORA2Aupregulation and baseline P50 amplitudes in theschizophrenia组。当前的一个主要发现飞行员study is the upregulation ofADORA2Aexpression following treatment with antipsychotics. In addition, this upregulation was predicted by baseline P50 amplitude, an observation that awaits replication in an expanded sample. |
| SCZ Keywords | schizophrenia |
| 5 | Transl Psychiatry 2013 -1 3: e321 |
| PMID | 24169640 |
| Title | Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. |
| Abstract | Whole-genome expression profiling in postmortem brain tissue has recently provided insight into the pathophysiology ofschizophrenia。Previous microarray and RNA-Seq studies identified several biological processes including synaptic function, mitochondrial function and immune/inflammation response as altered in the cortex of subjects withschizophrenia。Now using RNA-Seq data from the hippocampus, we have identified 144 differentially expressed genes inschizophreniacases as compared with unaffected controls. Immune/inflammation response was the main biological process over-represented in these genes. The upregulation of several of these genes, IFITM1, IFITM2, IFITM3, APOL1 (Apolipoprotein L1),ADORA2A(adenosine receptor 2A), IGFBP4 and CD163 were validated in theschizophreniasubjects using data from the SNCID database and with quantitative RT-PCR. We identified a co-expression module associated withschizophreniathat includes the majority of differentially expressed genes related to immune/inflammation response as well as with the density of parvalbumin-containing neurons in the hippocampus. The results indicate that abnormal immune/inflammation response in the hippocampus may underlie the pathophysiology ofschizophreniaand may be associated with abnormalities in the parvalbumin-containing neurons that lead to the cognitive deficits of the disease. |
| SCZ Keywords | schizophrenia |
| 6 | J Psychiatr Res 2014 Apr 51: 49-59 |
| PMID | 24433848 |
| Title | Reduced striatal adenosine A2A receptor levels define a molecular subgroup in schizophrenia. |
| Abstract | schizophrenia(深圳)是一个来历不明的精神障碍。一些scientific evidence seems to indicate that SZ is not a single disease entity, since there are patient groups with clear symptomatic, course and biomarker differences. SZ is characterized by a hyperdopaminergic state related to high dopamine D2 receptor activity. It has also been proposed that there is a hypoadenosynergic state. Adenosine is a nucleoside widely distributed in the organism with neuromodulative and neuroprotective activity in the central nervous system. In the brain, the most abundant adenosine receptors are A1R and A2AR. In the present report, we characterize the presence of both receptors in human postmortem putamens of patients suffering SZ with real time TaqMan PCR, western blotting and radioligand binding assay. We show that A1R levels remain unchanged with respect to age-matched controls, whereas nearly fifty percent of patients have reduced A2AR, at the transcriptional and translational levels. Moreover, we describe how DNA methylation plays a role in the pathological A2AR levels with the bisulfite-sequencing technique. In fact, an increase in 5-methylcytosine percentage in the 5' UTR region ofADORA2Awas found in those SZ patients with reduced A2AR levels. Interestingly, there was a relationship between the A2A/?-actin ratio and motor disturbances as assessed with some items of the PANSS, AIMS and SAS scales. Therefore, there may be a subgroup of SZ patients with reduced striatal A2AR levels accompanied by an altered motor phenotype. |
| SCZ Keywords | schizophrenia |
| 7 | OMICS 2016 May 20: 283-9 |
| PMID | 27195966 |
| Title | Adenosine Hypothesis of Antipsychotic Drugs Revisited: Pharmacogenomics Variation in Nonacute Schizophrenia. |
| Abstract | The existing antipsychotic therapy is based on dopamine hyperfunction and glutamate hypofunction hypotheses ofschizophrenia。Adenosine receptors (ADORA) have a neuromodulatory role and can control dopaminergic and glutamatergic systems. To elucidate the effect of ADORA polymorphisms on psychopathological symptoms and adverse effects in patients withschizophreniaon long-term antipsychotic treatment, we examined 127 nonacuteschizophreniaoutpatients in a cross-sectional study using the Positive and Negative Symptoms Scale, Simpson-Angus Scale, Barnes Akathisia Rating Scale, and Abnormal Involuntary Movement Scale. All patients were genotyped for 18 polymorphisms in ADORA1,ADORA2A, and ADORA3. We found an association between ADORA1 rs3766566 and psychopathological symptoms (p?=?0.006), in particular, with positive psychopathological symptoms (p?=?0.010) and general psychopathological symptoms (p?=?0.023), betweenADORA2Ars2298383 and general psychopathological symptoms (p?=?0.046), and betweenADORA2Ars5751876 and akathisia (p?=?0.015). Haplotype analysis showed an association between ADORA1 CTCAACG haplotype and overall psychopathological symptoms (p?=?0.019), positive psychopathological symptoms (p?=?0.021), and akathisia (p?=?0.028).ADORA2ATCCTC haplotype was associated with parkinsonism (p?=?0.014). ADORA3 CACTAC was associated with akathisia (p?=?0.042), whereas CACTAT was associated with akathisia (p?=?0.045) and tardive dyskinesia (p?=?0.023). The results of this first comprehensive study on ADORA polymorphisms in patients with nonacuteschizophreniareceiving long-term antipsychotic therapy suggest an important neuromodulatory role of ADORA receptors in both psychopathological symptoms and adverse effects of antipsychotics. |
| SCZ Keywords | schizophrenia |